Azelis stock trades 2.35% above latest report quote

Azelis stock traded at 11.75 euros on Lang & Schwarz at 18:11 CET on Wednesday, November 11, 2026, 2.35 percent above the 11.48 euros quoted in the latest AD HOC NEWS report at 10:02 CET the same day.

Growth Improves In The Third Quarter

The previous report described a stronger underlying third quarter for Azelis, with organic revenue growth accelerating and adjusted EBITA improving. Industrial Chemicals led the recovery, while performance across Life Sciences and regional markets remained uneven.

Management retained its target for positive organic adjusted EBITA growth in 2026. The company also reaffirmed medium-term ambitions for gross profit growth, adjusted EBITA expansion, higher earnings per share and a return on capital employed above 11.5 percent.

Americas Charge Raises The Stakes

A 350 million euro non-cash goodwill impairment linked mainly to Americas acquisitions reduced reported earnings, goodwill, assets and equity. The charge did not directly affect cash flow, working capital or net debt, but it highlights the execution risk attached to the regional portfolio.

Free cash flow weakened in the reported quarter as Azelis invested more working capital, including inventory to support demand recovery. Net debt and leverage therefore remain important variables for investors assessing whether improved operating momentum can translate into stronger cash generation.

What Investors Watch Next

The next focus is whether fourth-quarter working-capital normalisation and continued EBITA growth can improve cash conversion. A sustained recovery would support the operational case, while weak cash generation or persistent leverage would limit the scope for a re-rating.

For broader Belgian market context, investors can follow the BEL20 and current market reports.

More news and analyses on Azelis stock.